Summit Therapeutics Soars 10.24% on Citigroup Upgrade
1min read On April 23, 2025, Summit Therapeutics' stock surged by 10.24% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Citigroup recently upgraded Summit Therapeutics from a "neutral" rating to a "buy" rating, while also increasing their price target for the stock from $23.00 to $35.00. This move reflects a growing optimism about the company's prospects and potential for future growth.
Summit Therapeutics has seen a remarkable 843% increase in its stock price since the end of the 2023 fiscal year. This substantial gain is largely attributed to favorable changes in the company's revenue, which have driven investor confidence and market performance.
Analysts have noted that Summit Therapeutics has outperformed 53% of companies evaluated by MarketBeat, ranking 414th out of 916 stocks in the medical sector. This strong performance underscores the company's competitive position and potential for continued success in the market.
